Vir and GlaxoSmithKline begin pivotal study of Covid-19 antibody drug
Vir Biotechnology, a San Francisco-based firm focused on infectious disease, and GlaxoSmithKline, the British drug giant, said Monday that they are beginning a study of an antibody drug aimed at treating Covid-19.
The study will enroll 1,300 patients around the world who have early symptomatic infection, and will test whether the treatment, VIR-7831, can prevent those patients from being hospitalized. The companies said that they expect initial clinical results of the study by the end of 2020, meaning that the treatment, if effective, might be available for emergency use in early 2021.
Read Original Article: Vir and GlaxoSmithKline begin pivotal study of Covid-19 antibody drug »
